A Phase 4 interventional study of Ramipril in Chronic Kidney Disease and Heart Failure With Reduced Ejection Fraction (HFrEF), sponsored by Evi Liliek Wulandari. Recruiting at 1 site in Indonesia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-10.
Sponsored by Evi Liliek Wulandari · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Renal Insufficiency, Chronic with a site in Indonesia — 6 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency, Chronic · Indonesia.
Among the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia, this one is the 5th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, and was the 15th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →6 of the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Indonesia, United States, Argentina and 34 more countries
Ages 18+
Indiana University · Sites in Indonesia, United States, Argentina and 30 more countries
Ages 0 min–2 wk
Universitas Indonesia · Sites in Indonesia
Ages 18–59
Universitas Indonesia · Sites in Indonesia
Ages 18–59
Universitas Muhammadiyah Yogyakarta · Sites in Indonesia
Ages 18–65
A study can be open while its sites in Indonesia have not opened yet or have stopped. Only those recruiting at a site in Indonesia →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 3 · Phase 4 2
First in 2009; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 45 across the 16 interventional studies, 200 across the 7 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 23 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Evi Liliek Wulandari as lead sponsor.
Evi Liliek Wulandari has 1 study filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
3 of the studies in Renal Insufficiency, Chronic with a site in Indonesia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07888777Universitas IndonesiaManual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis | 2026-11 |
| NCT07887386Universitas IndonesiaManual Acupuncture for Intradialytic Fatigue in CKD Patients | 2026-12 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Renal Insufficiency, Chronic with a site in Indonesia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compares the effects of once-daily versus twice-daily ramipril dosing on renal function in chronic kidney disease (CKD) patients with heart failure with reduced ejection fraction (HFrEF). Outcomes include changes in plasma renin activity, malondialdehyde, interleukin-6, albuminuria, and cystatin C after 30 days of therapy.
Chronic kidney disease (CKD) frequently coexists with heart failure with reduced ejection fraction (HFrEF), characterized by neurohormonal activation, inflammation, oxidative stress, and progressive renal deterioration. Activation of the renin-angiotensin-aldosterone system (RAAS) contributes significantly to both renal and cardiac dysfunction. Ramipril, an ACE inhibitor, is widely recommended for CKD with albuminuria and HFrEF. However, discrepancies exist in guidelines regarding once-daily versus twice-daily administration. These differences may influence RAAS suppression effectiveness and patient adherence.
This randomized, double-blind, parallel assignment clinical trial investigates the impact of once-daily (10 mg every 24 hours) versus twice-daily (5 mg every 12 hours) ramipril dosing on renal biomarkers in CKD patients with HFrEF. Outcomes include plasma renin activity (PRA), malondialdehyde (MDA), interleukin-6 (IL-6), albuminuria, and cystatin C measured over a 30-day treatment period. The study aims to provide scientific evidence to support optimal ramipril dosing strategies that improve renal outcomes among patients with CKD and reduced ejection fraction heart failure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive ramipril 10 mg once daily for 30 days
Drug: Ramipril
Participants receive ramipril 5 mg twice daily for 30 days
Drug: Ramipril
Ramipril administered either as 10 mg once daily or 5 mg twice daily for 30 days
Also known as: ACE inhibitor
Change in Plasma Renin Activity (PRA)
Change in plasma renin activity from baseline to day 30.
Time frame: 30 days
Change in Malondialdehyde (MDA)
Change in plasma MDA levels as a biomarker of oxidative stress
Time frame: 30 days
Change in Interleukin-6 (IL-6)
Change in serum IL-6 levels as a marker of systemic inflammation
Time frame: 30 days
Change in Albuminuria
Change in albumin-creatinine ratio (ACR) from baseline to day 30
Time frame: 30 days
Change in Cystatin C
Change in serum cystatin C levels as a marker of glomerular filtration
Time frame: 30 days
Change in Serum Creatinine
Change in serum creatinine concentration from baseline to day 30, measured by standard hospital laboratory methods
Time frame: 30 days
Change in Estimated Glomerular Filtration Rate (eGFR)
Change in estimated glomerular filtration rate (eGFR) from baseline to day 30, calculated using the CKD-EPI equation
Time frame: 30 days
Change in Blood Pressure (Systolic and Diastolic)
Change in clinic-measured systolic and diastolic blood pressure from baseline to day 30
Time frame: 30 days
Incidence of Treatment-Related Adverse Events
Number and type of adverse events considered related to ramipril during 30 day treatment period (e.g. hyperkalemia), graded by severity
Time frame: 30 days
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Dec 2025, 6 months after the start.
Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's planned 6 months is below that.
Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramipril
Renal Insufficiency, Chronic →